Virakul Sita, Dalm Virgil A S H, Paridaens Dion, van den Bosch Willem A, Mulder Monique T, Hirankarn Nattiya, van Hagen P Martin, Dik Willem A
Department of Immunology Laboratory of Medical Immunology, Erasmus MC, Rotterdam, The Netherlands 2Internal Medicine, Division of Clinical Immunology, Erasmus MC, Rotterdam, The Netherlands.
Rotterdam Eye Hospital, Rotterdam, The Netherlands.
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5457-64. doi: 10.1167/iovs.15-17001.
Platelet-derived growth factor (PDGF)-BB has been identified as important factor in pathogenesis of Graves' ophthalmopathy (GO). It stimulates proliferation, cytokine, and hyaluronan production, and thyrotropin receptor expression by orbital fibroblasts. Therefore, the PDGF-pathway has been proposed as a target for pharmacological intervention in GO. However, increased adipogenesis is another major pathological characteristic of GO and it is unknown whether this is affected by PDGF-BB. The aim of this study was to investigate the effect of PDGF-BB on adipocyte differentiation by orbital fibroblasts.
Orbital fibroblasts from five healthy controls and nine GO patients were collected. Adipogenesis was induced by culturing orbital fibroblasts in differentiation medium, either in the presence or absence of PDGF-BB. Adipogenesis was determined by Oil-Red-O staining, triglyceride measurement, and peroxisome proliferator-activated receptor (PPAR)-γ mRNA expression.
Platelet-derived growth factor-BB significantly enhanced adipocyte differentiation by orbital fibroblasts (Oil-Red-O staining [P < 0.0001], triglyceride measurement [P < 0.05], and PPAR-γ mRNA expression [P < 0.05]). It enhanced IL-6 production early during differentiation, but the effect of PDGF-BB on adipogenesis was independent of autocrine IL-6 signaling as it was not abrogated by IL-6-receptor-α neutralizing antibody. The clinically applicable tyrosine kinase inhibitor dasatinib and tyrphostin AG1296, which both block PDGF receptor tyrosine kinase activity, inhibited PDGF-BB-enhanced adipogenesis (P < 0.05) in orbital fibroblasts. Moreover, dasatinib reduced PPAR-γ mRNA expression in cultured GO orbital tissue.
Platelet-derived growth factor-BB enhances adipogenesis in orbital fibroblasts, and, thus, may contribute to adipose tissue expansion in GO. Therefore, the PDGF-signaling cascade may represent a target of therapy to interfere with adipogenesis in GO.
血小板衍生生长因子(PDGF)-BB已被确定为格雷夫斯眼病(GO)发病机制中的重要因素。它可刺激眼眶成纤维细胞的增殖、细胞因子及透明质酸生成,以及促甲状腺激素受体表达。因此,PDGF途径已被提议作为GO药物干预的靶点。然而,脂肪生成增加是GO的另一个主要病理特征,尚不清楚这是否受PDGF-BB影响。本研究的目的是探讨PDGF-BB对眼眶成纤维细胞脂肪细胞分化的影响。
收集来自5名健康对照者和9名GO患者的眼眶成纤维细胞。通过在分化培养基中培养眼眶成纤维细胞来诱导脂肪生成,培养基中添加或不添加PDGF-BB。通过油红O染色、甘油三酯测定和过氧化物酶体增殖物激活受体(PPAR)-γ mRNA表达来确定脂肪生成。
血小板衍生生长因子-BB显著增强眼眶成纤维细胞的脂肪细胞分化(油红O染色[P<0.0001]、甘油三酯测定[P<0.05]和PPAR-γ mRNA表达[P<0.05])。它在分化早期增强白细胞介素(IL)-6生成,但PDGF-BB对脂肪生成的影响不依赖于自分泌IL-6信号,因为IL-6受体-α中和抗体并未消除该影响。临床适用的酪氨酸激酶抑制剂达沙替尼和 tyrphostin AG1296均可阻断PDGF受体酪氨酸激酶活性,二者均抑制眼眶成纤维细胞中PDGF-BB增强的脂肪生成(P<0.05)。此外,达沙替尼降低了培养的GO眼眶组织中PPAR-γ mRNA表达。
血小板衍生生长因子-BB增强眼眶成纤维细胞的脂肪生成,因此可能有助于GO中脂肪组织的扩张。因此,PDGF信号级联可能代表了一种干预GO中脂肪生成的治疗靶点。